Bellefontaine boy part of medical breakthrough

5-year-old receives first dose of treatment for Duchenne Muscular Dystrophygene therapy developed at Nationwide Children’s Hospital

COLUMBUS – In a landmark moment for the Abigail Wexner Research Institute at Nationwide Children’s, a 5-year-old from Bellefontaine received the first dose of a recently approved gene therapy for Duchenne muscular dystrophy at Nationwide Children’s Hospital, where the therapy was invented and initially tested.

Five-year-old Gideon Griffiths received the first infusion of ELEVIDYS (SRP-9001) at Nationwide Children’s. Gideon was diagnosed with Duchenne muscular dystrophy (DMD) at birth. He is among the first group of patients across the country to receive the gene therapy since its accelerated approval by the U.S. Food and Drug Administration (FDA) in June. Nationwide Children’s has invented two of the first eight gene therapies approved by the FDA.

“This is a meaningful day not only for these first families, but for families battling DMD everywhere,” said Jerry Mendell, MD, principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute, and co-inventor of ELEVIDYS, noting that 50 years of work went into this research.

“It is thrilling to arrive at this moment of getting treatment to a patient population that has waited so long for more hope.”

“It’s life changing to be able to experience this, to be able to give Gideon a better quality of life,” said Erin Griffiths, Gideon’s mother. “We feel hopeful and thankful, and we’re excited to watch our little boy run around, play and just be a boy.

Five-year-old Gideon Griffiths receives the first infusion of ELEVIDYS (SRP-9001) from Dr. Jerry Mendell at Nationwide Children’s Hospital since its accelerated FDA approval in June 2023, while seated next to his mother Erin. (NATIONWIDE CHILDREN’S HOSPITAL PHOTO)

“We can’t thank Dr. Mendell enough for everything he’s done. We’re very blessed to have everyone who works with us.”

The therapy, developed, tested and patented at Nationwide Children’s marks an extraordinary achievement in the field of neuromuscular medicine and provides a life-altering treatment for children with Duchenne muscular dystrophy. This is the second gene therapy developed at Nationwide Children’s to receive FDA approval, two of only eight to have received FDA approval to date.

Dr. Mendell noted the advantages of gene therapy over traditional drug therapy.

“We can get to the disease before it wipes out all of the nerve and muscle,” he said Duchenne muscular dystrophy is a severe form of muscular dystrophy caused by a mutation in the DMD gene, resulting in a lack of the dystrophin protein, leading to muscle weakness and atrophy. Muscle weakness may affect the skeletal muscle and the heart muscle. As an X-linked condition, DMD typically affects boys and is progressive; over time, children with DMD develop problems with walking, breathing and heart function.

SRP-9001 is a novel DMD gene-replacement therapy co-developed by Dr. Mendell and Louise Rodino-Klapac, PhD, formerly at Nationwide Children’s and currently the executive vice president, head of Research and Development, and chief scientific officer at Sarepta Therapeutics. This gene therapy program was licensed by Sarepta in 2018.

The therapy, an intravenous infusion of ELEVIDYS, packages a micro-dystrophin gene into an adeno-associated virus serotype (AAVrh74, which was isolated at Nationwide Children’s) to deliver missing or corrected genes to cells.